Contralateral recurrence of tumefactive demyelination
نویسندگان
چکیده
منابع مشابه
Tumefactive demyelination.
We present a case of 22 year old female who had pulmonary tuberculosis followed by tuberculous meningitis and tuberculomas in past. This time she presented to us with right hemiparesis and altered sensorium. Diagnosis of tumefactive demyelination was made on the basis of typical MRI findings. Patient showed good response to steroids.
متن کاملTumefactive demyelination of the spinal cord.
Demyelinating lesions of the brain have been frequently reported to mimic tumors, whereas very few cases of tumefactive demyelination of the spine have been reported. We report a patient with tumefactive demyelination of the spinal cord who was clinically, by MRI, and by frozen section diagnosed with tumor and had complete surgical resection. Hence patients with spinal cord lesions suspicious o...
متن کاملA rare presentation of atypical demyelination: tumefactive multiple sclerosis causing Gerstmann’s syndrome
BACKGROUND Tumefactive demyelinating lesions are a rare manifestation of multiple sclerosis (MS). Differential diagnosis of such space occupying lesions may not be straightforward and sometimes necessitate brain biopsy. Impaired cognition is the second most common clinical manifestation of tumefactive MS; however complex cognitive syndromes are unusual. CASE PRESENTATION We report the case of...
متن کاملFavourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell response.
We report a case of multiple sclerosis-associated fulminant tumefactive demyelinating lesion (TDL) with the special feature of delayed humoral immune response. Plasma exchange (PE) yielded significant benefit in two consecutive steroid-unresponsive relapses, while signs of an intrathecal B-cell response were only present 2 years later at the second relapse. Remission was achieved and sustained ...
متن کاملTumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
Finglimod, a sphingosine 1-phosphate receptor modulator, is the first orally administered therapy approved for prophylaxis in multiple sclerosis (MS). Several reports in the last two years suggested that it might be associated with severe augmentation of disease activity upon initiation or discontinuation of therapy. We present an MS patient who developed a giant cavitating brain lesion under f...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Neuroradiology Journal
سال: 2015
ISSN: 1971-4009,2385-1996
DOI: 10.1177/1971400915609798